Sonnet BioTherapeutics (SONN) EBITDA (2010 - 2025)
Sonnet BioTherapeutics (SONN) EBITDA from Jun 30, 2010 to Sep 30, 2025. The TTM Sonnet BioTherapeutics (SONN) EBITDA is -$16M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Sonnet BioTherapeutics (SONN) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +33.78% |
| 3 Years TTM | -18.87% |
| 5 Years TTM | -8.16% |
| 10 Years TTM | +9.92% |
| All Time TTM | +40.07% |
Annual EBITDA change of Sonnet BioTherapeutics (SONN)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$16M | +33.70% |
| 2024 | -$12M | -36.95% |
| 2023 | -$19M | -36.68% |
| 2022 | -$30M | +18.31% |
| 2021 | -$25M | +3.47% |
| 2020 | -$24M | +70.15% |
| 2019 | -$14M | +301.13% |
| 2018 | -$3.55M | +20.34% |
| 2017 | -$2.95M | +953.57% |
| 2016 | -$280K | -91.72% |
| 2015 | -$3.38M | -14.65% |
| 2014 | -$3.96M | -0.50% |
| 2013 | -$3.98M | +80.09% |
| 2012 | -$2.21M | +151.14% |
| 2011 | -$880K | -16.19% |
| 2010 | -$1.05M | N/A |
Comparison Sonnet BioTherapeutics (SONN) five years EBITDA CAGR with competitors
Sonnet BioTherapeutics (SONN) five years EBITDA CAGR is -8.16%.